Praxis Plans Epilepsy Drug Launch With A Proposed Annual List Price Of Up To $600,000

The company also proposed $50,000–$100,000 a year for its essential-tremor drug as both treatments await FDA decisions.

Share
Praxis Plans Epilepsy Drug Launch With A Proposed Annual List Price Of Up To $600,000

Praxis Precision Medicines, which develops medicines for epilepsy and movement disorders, outlined a proposed annual list price of $400,000–$600,000 Thursday for relutrigine, its treatment candidate for SCN2A- and SCN8A-related developmental epilepsies. The company described its launch preparations in an SEC filing, with commercialization dependent on FDA approval.

Two Prices, Two Launch Models

Praxis proposed an annual list price of $50,000–$100,000 for ulixacaltamide, its essential-tremor candidate. Both ranges represent prices before rebates and discounts.

The company estimates about 9 million Americans have essential tremor and plans to focus initially on about 2 million seeking treatment. Its planned field team of approximately 300 people would reach about 19,000 health care professionals, backed by connected prescription intake, patient services and specialty pharmacies.

Relutrigine would use a more specialized approach centered on pediatric neurologists and treatment centers, with individual support for families and a single specialty pharmacy. Praxis estimates more than 10,000 people have SCN2A- or SCN8A-related developmental epilepsies, including about 5,000 diagnosed patients.

Praxis built its business around genetic insights into disrupted brain-cell activity. Its Cerebrum platform develops oral medicines; Solidus develops medicines that act on RNA to alter gene expression. Its clinical portfolio also includes vormatrigine for common epilepsies and elsunersen for severe genetic epilepsy.

Longer Follow-Up, Different Evidence

Relutrigine’s extension study showed an 86% reduction in motor seizures from baseline at 18 months. That follow-up had no placebo comparison, and 10 participants contributed to the month-18 reading. Separately, the controlled study showed a 53% placebo-adjusted reduction in motor seizures.

Ulixacaltamide’s early long-term analysis covered 68 participants assessed after approximately 95 weeks of treatment. Daily-function scores showed sustained and increasing improvement among those completing the recent assessments.

The main ulixacaltamide trial result stayed statistically significant under all four model-based sensitivity analyses presented, including checks the FDA requested during its review. Those analyses test how different assumptions affect the result.

The clinical foundation includes a withdrawal study Praxis previously reported in its August 6 presentation: 55% retained their response on ulixacaltamide, versus 33% on placebo. Participants had already responded before randomization, so that study tested whether the benefit persisted.

Expansion Beyond The Pending Launches

Praxis plans ulixacaltamide studies in Parkinson’s disease, restless legs syndrome and autism spectrum disorder in 2027. The company expects initial human testing of two additional movement-disorder molecules that year and plans clinical testing of an ulixacaltamide patch with Remagine Labs, its delivery-technology collaborator.

Pain candidate PRAX-215 is in early-stage testing, with results expected in 2027. Praxis plans human testing of its other pain candidate, PRAX-110, in 2028. PRAX-206, targeting KCNT1-related developmental epilepsies, is scheduled to enter human testing in early 2027.

Solidus now includes six preclinical programs beyond elsunersen, which is in a pivotal study: PRAX-080 targets PCDH19, PRAX-090 targets SYNGAP1, PRAX-100 targets SCN2A loss-of-function disorders, PRAX-120 targets ataxia-telangiectasia, PRAX-130 targets SLC6A1 and PRAX-140 targets KCNQ2. Praxis expects pivotal elsunersen results and an FDA approval application in 2027.

The FDA’s target decision dates are December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide. Those are review targets, not promises of approval.

Sources

More on Praxis Precision Medicines

All Praxis Precision Medicines (PRAX) coverage →